LRRK2
LRRK2 inhibitors are compounds that target and inhibit the activity of Leucine-Rich Repeat Kinase 2 (LRRK2), an enzyme involved in several cellular processes, including autophagy, vesicle trafficking, and inflammation. Mutations in the LRRK2 gene are associated with an increased risk of developing Parkinson's disease, making LRRK2 a significant target for neurodegenerative disease research. Inhibitors of LRRK2 are crucial for exploring its role in Parkinson's disease and for developing potential therapeutic strategies. At CymitQuimica, we offer a selection of LRRK2 inhibitors to support your research in neurodegeneration, kinase signaling, and therapeutic development.
Found 41 products of "LRRK2"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
MLi-2
CAS:MLi-2: Novel, potent CNS-active LRRK2 inhibitor; IC50s: 0.76nM in vitro, 1.4nM cellular, 3.4nM binding.Formula:C21H25N5O2Purity:98.96%Color and Shape:SolidMolecular weight:379.46BIX 02565
CAS:BIX 02565 is a potent inhibitor of ribosomal S6 kinase 2 (RSK2, IC50: 1.1 nM).Formula:C26H30N6O2Purity:97.44% - 99.7%Color and Shape:SolidMolecular weight:458.56JH-XII-03-02
CAS:JH-XII-03-02 is a potent and selective leucine-rich repeat kinase 2 (LRRK2) proteolysis targeting chimera (PROTAC) degrader, utilized in Parkinson's Disease (PDFormula:C43H51N9O10Purity:98%Color and Shape:SolidMolecular weight:853.92XL01126
XL01126 degrades LRRK2 (DC50: 14 nM G2019S, 32 nM WT), crosses the blood-brain barrier, aiding Parkinson's studies.Formula:C50H64ClFN10O6S2Color and Shape:SolidMolecular weight:1019.69RN341
RN341 is a LRRK2-specific type II kinase inhibitor (IC50 of 296 nM). It prevents the phosphorylation of LRRK2 by stabilizing an open conformation, thereby avoiding S935 dephosphorylation. Additionally, RN341 rescues LRRK2-mediated kinesin motility blockage by preventing microtubule binding. This compound effectively inhibits both wild-type and G2019S LRRK2 at the cellular level, offering a novel avenue for Parkinson's disease research.Color and Shape:Odour SolidRN277
RN277 is an inhibitor of LRRK2 type II kinase (LRRK2type II kinase). It serves as a cellular tool targeting the inactive state of LRRK2. In vitro, RN277 inhibits LRRK1 kinase activity and the kinase activity of LRRK2, with an IC50 of 70 nM. Additionally, it reduces Rab8a phosphorylation in a dose-dependent manner. RN277 is useful for Parkinson's disease research.Color and Shape:Odour SolidCZC-54252 hydrochloride
CAS:CZC-54252 hydrochloride: selective LRRK2 inhibitor; IC50 = 1.85/1.28 nM (wild-type/G2019S); neuroprotective; EC50 = 1 nM for G2019S injury.Formula:C22H26Cl2N6O4SPurity:98.21%Color and Shape:SolidMolecular weight:541.45EB-42486
CAS:EB-42486 is an effective and highly selective inhibitor of G2019S-LRRK2 with an IC50 < 0.2 nM.Formula:C22H22N8OPurity:99.53%Color and Shape:SolidMolecular weight:414.46LRRK2 inhibitor 1
CAS:<p>LRRK2 inhibitor 1 is a selective and potent LRRK2 inhibitor with an IC50 of 13 nM.LRRK2 inhibitor 1 inhibits DCLK1 kinase with an IC50 value of 2.61 nM.</p>Formula:C20H23N5O4Purity:99.94%Color and Shape:SolidMolecular weight:397.43Anti-LRRK2 Antibody (1C773)
Anti-LRRK2 Antibody (1C773) is an antibody targeting LRRK2. Anti-LRRK2 Antibody (1C773) can be used in ELISA, IHC.Color and Shape:Odour LiquidGSK2578215A
CAS:GSK2578215A is a potent and selective LRRK2 kinase inhibitor.Formula:C24H18FN3O2Purity:99.57% - 99.94%Color and Shape:SolidMolecular weight:399.42GNE-7915 tosylate
CAS:GNE-7915 tosylate is a potent, selective, and brain-penetrant LRRK2 inhibitor, boasting an IC50 value of 9 nM.Formula:C26H29F4N5O6SColor and Shape:SolidMolecular weight:615.6PF-06447475
CAS:PF-06447475 is a highly effective, specific, brain penetrant LRRK2 inhibitor with IC0 of 3/11 nM for wild type LRRK2 and G2019S LRRK2 respectively.Formula:C17H15N5OPurity:98.61% - 99.62%Color and Shape:SolidMolecular weight:305.33GNE-9605
CAS:<p>GNE-9605 is a highly effective, specifical, and brain-penetrant LRRK2 inhibitor (IC50: 19 nM).</p>Formula:C17H20ClF4N7OPurity:98.55% - 98.75%Color and Shape:SolidMolecular weight:449.83GNE-7915
CAS:GNE-7915 is a highly potent, selective and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) inhibitor.Formula:C19H21F4N5O3Purity:98% - ≥95%Color and Shape:SolidMolecular weight:443.4GNE0877
CAS:GNE0877 (GNE 0877) is a highly effective and specific leucine-rich repeat kinase 2 (LRRK2) inhibitor (Ki: 0.7 nM).Formula:C14H16F3N7Purity:98.01% - 99.97%Color and Shape:SolidMolecular weight:339.32PF-06454589
CAS:PF-06454589 is a potent inhibitor of LRRK2.Formula:C14H16N6OPurity:99.06%Color and Shape:SolidMolecular weight:284.32HG-10-102-01
CAS:HG-10-102-01 is an inhibitor of leucine-rich repeat kinase 2 (LRRK2, IC50 of 20.3 nM).Formula:C17H20ClN5O3Purity:99.59%Color and Shape:SolidMolecular weight:377.83CZC-25146 hydrochloride
CAS:<p>CZC-25146 is a selective LRRK2 inhibitor with IC50 of 4.76 nM/6.87 nM for wild type LRRK2 and G2019S LRRK2, respectively.</p>Formula:C22H26ClFN6O4SPurity:98.76%Color and Shape:SolidMolecular weight:525CZC-54252
CAS:CZC-54252 is a potent inhibitor of LRRK2.Formula:C22H25ClN6O4SPurity:99.39%Color and Shape:SolidMolecular weight:504.99JH-II-127
CAS:JH-II-127 is an oral LRRK2 inhibitor with IC50s: 6.6 nM (WT), 2.2 nM (G2019S), 47.7 nM (A2016T).Formula:C19H21ClN6O3Purity:98.32%Color and Shape:SolidMolecular weight:416.86IKK 16
CAS:IKK 16 (IKK Inhibitor VII) is a selective IκB kinase (IKK) inhibitor for IKK-2, IKK complex and IKK-1 with IC50 of 40 nM, 70 nM and 200 nM, respectively.Formula:C28H29N5OSPurity:98.76% - 99.61%Color and Shape:SolidMolecular weight:483.63CZC-25146
CAS:CZC-25146, a stable LRRK2 inhibitor, IC50: 4.76 nM (wild-type), 6.87 nM (G2019S).Formula:C22H25FN6O4SPurity:97.68%Color and Shape:SolidMolecular weight:488.54LRRK2-IN-1
CAS:LRRK2-IN-1 is an effective and selective LRRK2 inhibitor.Formula:C31H38N8O3Purity:98% - 98.82%Color and Shape:SolidMolecular weight:570.69PFE-360
CAS:<p>PFE-360 (PF-06685360) is a potent and selective inhibitor of LRRK2 kinase (IC50: 2.3 nM in vivo).</p>Formula:C16H16N6OPurity:98.14% - 99.73%Color and Shape:SolidMolecular weight:308.34PF-06371900
CAS:<p>PF-06371900 is a potent and highly selective inhibitor of leucine-rich repeat kinase 2 (LRRK2).</p>Formula:C17H16N6O2SColor and Shape:SolidMolecular weight:368.41PF-06455943
CAS:PF-06455943: LRRK2 inhibitor, IC50=3nM, PET radioligand, used for ADME/neuro PK & Parkinson's research.Formula:C17H14FN5OColor and Shape:SolidMolecular weight:323.32LRRK2-IN-10
CAS:LRRK2-IN-10 (compound 34) is a potent, mutation-selective, brain-penetrant inhibitor targeting G2019S-LRRK2 kinase with IC50 values of 11 nM for G2019S-LRRK2Formula:C20H15N5OPurity:98%Color and Shape:SolidMolecular weight:341.37LRRK2-IN-7
CAS:LRRK2-IN-7: potent, selective CNS-active LRRK2 inhibitor, IC50 0.9 nM, >1000x selectivity vs kinases/channels/CYPs.Formula:C24H26N6OPurity:99.26%Color and Shape:SolidMolecular weight:414.5LRRK2-IN-6
LRRK2-IN-6 is an oral, selective LRRK2 inhibitor crossing the blood-brain barrier, targeting GS (IC50: 4.6μM) and WT LRRK2 (IC50: 49μM).Formula:C23H24F2N4O2SColor and Shape:SolidMolecular weight:458.52LRRK2-IN-5
LRRK2-IN-5 is an oral, BBB-penetrating selective inhibitor for LRRK2 with IC50s: 1.2μM (GS) and 16μM (WT); halts LRRK2 autophosphorylation.Formula:C24H26F2N4O2SColor and Shape:SolidMolecular weight:472.55SRI-31255
CAS:SRI-31255 is an orally active LRRK2 inhibitor, with IC50 values of 520 nM for human wild-type (WT) and 427 nM for the G2019S mutant. It inhibits kinase activity by binding to the ATP-binding pocket of LRRK2, providing neuroprotective effects. SRI-31255 serves as a lead compound for developing LRRK2-targeted therapies for Parkinson’s disease research.Formula:C15H14N4Color and Shape:SolidMolecular weight:250.30LRRK2-IN-12
CAS:LRRK2-IN-12 (compound 1) is a potent inhibitor of LRRK2 (G20195) with an IC 50 of 0.45 nM, LRRK2 WT with an IC 50 of 1.1 nM, and LRRK2 WT ADP-Glo with an IC 50 of 0.46 nM. This compound is utilized in research related to Alzheimer's Disease [1].Formula:C18H17ClN8O2Color and Shape:SolidMolecular weight:412.83LRRK2-IN-4
CAS:LRRK2-IN-4: Potent, selective LRRK2 inhibitor, oral, BBB-penetrating, IC50=2.6 nM, potential for Parkinson's.Formula:C25H29ClF2N6O2Color and Shape:SolidMolecular weight:518.99LRRK2-IN-13
CAS:LRRK2-IN-13 (Compound 13), with an IC50 value of 0.57 nM, serves as an inhibitor of LRRK2 and exhibits properties that allow it to penetrate the brain [1].Formula:C19H19ClN8O2Color and Shape:SolidMolecular weight:426.86LRRK2-IN-14
CAS:LRRK2-IN-14 (Compound 8), an orally active inhibitor of LRRK2, exhibits an IC 50 of 6.3 nM against LRRK2(G2019S) cell activity and demonstrates inhibitory effects on hERG with an IC 50 of 22 μM. Additionally, LRRK2-IN-14 is permeable to the blood-brain barrier [1].Formula:C17H18F3N5O2Color and Shape:SolidMolecular weight:381.35(R,R)-LRRK2-IN-7
CAS:(R,R)-LRRK2-IN-7 is an isomer of LRRK2-IN-7, a potent and selective LRRK2 kinase inhibitor with CNS penetrance. It exhibits an IC50 of 0.9 nM and demonstrates over 1000-fold selectivity compared to other kinases, ion channels, and CYP enzymes.Formula:C24H26N6OMolecular weight:414.50LRRK2-IN-20
CAS:LRRK2-IN-20 (EX. 4.64) is a selective inhibitor of LRRK2 with a potency of pIC50 at 0.7921 nM. This compound is applicable in research studies focused on Parkinson's Disease (PD).Formula:C24H32ClN7OColor and Shape:SolidMolecular weight:470.01LRRK2-IN-16
CAS:<p>LRRK2-IN-16 (compound 25) is an inhibitor of the LRRK2 kinase with an IC50 value of less than 5 μM. It is applicable for research in neurodegenerative and autoimmune diseases.</p>Formula:C18H19N5OSColor and Shape:SolidMolecular weight:353.441LRRK2-IN-2
CAS:LRRK2-IN-2: selective, potent LRRK2 inhibitor, IC50 of 0.6 nM, oral, crosses blood-brain barrier, for Parkinson's research.Formula:C23H23Cl2F3N6O2Color and Shape:SolidMolecular weight:543.37LRRK2-IN-3
CAS:LRRK2-IN-3: potent, selective oral LRRK2 blocker, BBB-penetrant, IC50 of 0.6 nM in hPBMCs, for Parkinson's research.Formula:C25H29ClF2N6O2Color and Shape:SolidMolecular weight:518.99
